TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04696575: Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Sponsor: Roswell Park Cancer Institute · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 28 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT04696575 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04696575 Rescue Dossier →